RxDoctor Payments Data

Kerry Shaver, MD

Internal Medicine · Thibodaux, LANPI 1285805952

Payments from drug & device makers

$5,877in general payments, 2019–2025

Across 364 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$981
  • GSK$336
  • Amgen$322
  • Lilly USA, LLC$303
  • Esperion Therapeutics, Inc.$263
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$5,79299%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,877 in reported general payments places this provider in the 85th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$9,492
Medicare patients
21
Services billed
122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$58,855
JardianceEmpagliflozin38$42,688
XifaxanRifaximin12$37,740
MounjaroTirzepatide13$19,955
EliquisApixaban15$18,030
RybelsusSemaglutide12$16,688
LinzessLinaclotide22$15,656
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,221
TradjentaLinagliptin20$12,582
Soliqua 100-33Insulin Glargine/Lixisenatide11$7,834
Varenicline Tartrate14$3,975
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,192
Albuterol Sulfate HfaAlbuterol Sulfate57$1,952
Omeprazole77$1,099
Gabapentin89$1,043

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$981$75,54359 claims
Boehringer IngelheimJardiance, Tradjenta$179$55,27058 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$96$37,74012 claims
Lilly USA, LLCMounjaro$303$19,95513 claims
PfizerEliquis$221$18,03015 claims
AbbVieLinzess$1,097$15,65622 claims
GSKTrelegy Ellipta$336$13,22117 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$214$7,83411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Thibodaux

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →